NEW YORK, NY / ACCESSWIRE / April 27, 2018 / Genprex shares skyrocketed on Thursday on significant volume traded. It was just weeks ago that the company made its IPO debut. Genprex also announced this week that it has established offices in Massachusetts to help accelerate the clinical development of Oncoprex, its lead immunogene therapy for non-small cell lung cancer. Shares of Celgene also saw gains after a report discussed that Juno Therapeutics' CEO quietly stepped down from his role and joined Celgene's board.
RDI Initiates Coverage on:
Genprex, Inc. shares closed up nearly 87% on almost 4 million shares traded on Thursday. Shares have been on a rocket for the clinical-stage gene therapy company, which closed its initial public offering on April 3 of an aggregate of 1,280,000 shares of common stock at a public offering price of $5.00 a share, before underwriting discounts. The company also announced on Wednesday that it has established offices in Cambridge, Mass. to help accelerate the clinical development of its lead drug candidate, Oncoprex™, an immunogene therapy for the treatment of non-small cell lung cancer (NSCLC). The company's newly appointed President and Chief Operating Officer, Julien Pham, MD, MPH, commented, "We are excited to establish a footprint in Cambridge, a global center of excellence in life sciences with a highly specialized talent pool. From here, we will advance a number of business activities to support the clinical development of Oncoprex for the treatment of non-small cell lung cancer."
Access RDI's Genprex, Inc. Research Report at:
Celgene Corporation shares closed up 3.23% on about 5.2 million shares traded. There was no remarkable news from the company but it was revealed that Juno Therapeutics co-founder and CEO Hans Bishop has stepped down as President and CEO of the company. It was in a regulatory filing last week from Celgene that revealed he was appointed to Celgene's board. Celgene acquired Juno Therapeutics for $9 billion not too long ago. In early March, Chairman and CO of Celgene, Mark J. Alles, commented, "Our colleagues at Juno are developing some of the most promising approaches to treating cancer, and we are excited to add their pioneering work to Celgene's leading hematology and oncology research and commercial platform. Together, we expect to expand our opportunities to discover and develop new therapies that will improve and extend the lives of patients worldwide."
Access RDI's Celgene Corporation Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.